• DOI:10.1111/j.1460-9568.1995.tb00712.x
• Corpus ID: 10181885

Activation of Class II or III Metabotropic Glutamate Receptors Protects Cultured Cortical Neurons Against Excitotoxic Degeneration

@article{Bruno1995ActivationOC,
  title={Activation of Class II or III Metabotropic Glutamate Receptors Protects Cultured Cortical Neurons Against Excitotoxic Degeneration},
  author={Valeria Bruno and Giuseppe Battaglia and Agata Copani and R. G. Giffard and Giuseppina Raciti and Rocco Raffaele and Haruhiko Shinozaki and Ferdinando Nicoletti},
  journal={European Journal of Neuroscience},
  year={1995},
  volume={7}
}

• V. Bruno, G. Battaglia, +5 authors F. Nicoletti
• Published 1 September 1995
• Biology
• European Journal of Neuroscience

Trans‐1‐aminocyclopentane‐1,3‐dicarboxylic acid, a mixed agonist of all metabotropic glutamate receptor (mGluR) subtypes, is known to produce either neurotoxic or neuroprotective effects. We have therefore hypothesized that individual mGluR subtypes differentially affect neurodegenerative processes. Selective agonists of subtypes which belong to mGluR class II or III, such as (2s, 1′R,2′R,3′R)‐2‐(2,3‐dicarboxycyclopropyl)‐glycine (DCG‐IV) (specific for subtypes mGluR2 or 3) or L‐2‐amino‐4‐phosphonobutanoate and L‐serine‐O‐phosphate (specific for subtypes mGluR4, 6 or 7), were highly potent and efficacious in protecting cultured cortical neurons against toxicity induced by either a transient exposure to N‐methyl‐D‐aspartate (NMDA) or a prolonged exposure to kainate. In contrast, agonists that preferentially activate class I mGluR subtypes (mGluR1 or 5), such as quisqualate or trans‐azetidine‐2,3‐dicarboxylic acid, were inactive. DCG‐IV was still neuroprotective when applied to cultures after the toxic pulse with NMDA. This delayed rescue effect was associated with a reduction in the release of endogenous glutamate, a process that contributes to the maturation of neuronal damage. We conclude that agonists of class II or III mGluRs are of potential interest in the experimental therapy of acute or chronic neurodegenerative disorders.